Platinum-doublet chemotherapy followed by pembrolizumab therapy for lung cancer with lymphangitis carcinomatosa mimicking interstitial pneumonitis: A case report

RATIONALE: Pembrolizumab, an immune-checkpoint inhibitor (ICI), has been shown to be effective for treatment-naive patients with non–small cell lung cancer (NSCLC) and high expression of programmed death-ligand 1 (PD-L1). Therefore, treatment regimens containing pembrolizumab have become a standard...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamasaki, Masahiro, Funaishi, Kunihiko, Kawamoto, Kazuma, Matsumoto, Yu, Matsumoto, Naoko, Taniwaki, Masaya, Ohashi, Nobuyuki, Hattori, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831270/
https://www.ncbi.nlm.nih.gov/pubmed/31415404
http://dx.doi.org/10.1097/MD.0000000000016834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831270/
https://www.ncbi.nlm.nih.gov/pubmed/31415404
http://dx.doi.org/10.1097/MD.0000000000016834

Ejemplares similares